Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies
The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 a...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-12-01
|
| Series: | OncoImmunology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127284 |
| _version_ | 1811181747937738752 |
|---|---|
| author | Rebecca Adams Gabriel Osborn Bipashna Mukhia Roman Laddach Zena Willsmore Alicia Chenoweth Jenny L C Geh Alastair D MacKenzie Ross Ciaran Healy Linda Barber Sophia Tsoka Victoria Sanz-Moreno Katie E Lacy Sophia N Karagiannis |
| author_facet | Rebecca Adams Gabriel Osborn Bipashna Mukhia Roman Laddach Zena Willsmore Alicia Chenoweth Jenny L C Geh Alastair D MacKenzie Ross Ciaran Healy Linda Barber Sophia Tsoka Victoria Sanz-Moreno Katie E Lacy Sophia N Karagiannis |
| author_sort | Rebecca Adams |
| collection | DOAJ |
| description | The application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 and CTLA-4. However, more than half of patients do not benefit from treatment. Targeting the prominent myeloid compartment within the tumor microenvironment, and in particular the ever-abundant tumor-associated macrophages (TAMs), may be a promising strategy to complement existing therapies and enhance treatment success. TAMs are a highly diverse and plastic subset of cells whose pro-tumor properties can support melanoma growth, angiogenesis and invasion. Understanding of their diversity, plasticity and multifaceted roles in cancer forms the basis for new promising TAM-centered treatment strategies. There are multiple mechanisms by which macrophages can be targeted with antibodies in a therapeutic setting, including by depletion, inhibition of specific pro-tumor properties, differential polarization to pro-inflammatory states and enhancement of antitumor immune functions. Here, we discuss TAMs in melanoma, their interactions with checkpoint inhibitor antibodies and emerging mAbs targeting different aspects of TAM biology and their potential to be translated to the clinic. |
| first_indexed | 2024-04-11T09:22:48Z |
| format | Article |
| id | doaj.art-96ec4ae35e51463cbf1b5510ddb115e2 |
| institution | Directory Open Access Journal |
| issn | 2162-402X |
| language | English |
| last_indexed | 2024-04-11T09:22:48Z |
| publishDate | 2022-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | OncoImmunology |
| spelling | doaj.art-96ec4ae35e51463cbf1b5510ddb115e22022-12-22T04:32:07ZengTaylor & Francis GroupOncoImmunology2162-402X2022-12-0111110.1080/2162402X.2022.2127284Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodiesRebecca Adams0Gabriel Osborn1Bipashna Mukhia2Roman Laddach3Zena Willsmore4Alicia Chenoweth5Jenny L C Geh6Alastair D MacKenzie Ross7Ciaran Healy8Linda Barber9Sophia Tsoka10Victoria Sanz-Moreno11Katie E Lacy12Sophia N Karagiannis13St. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKDepartment of Plastic Surgery at Guy’s, King’s, and St. Thomas’ Hospitals, London, UKDepartment of Plastic Surgery at Guy’s, King’s, and St. Thomas’ Hospitals, London, UKSchool of Cancer & Pharmaceutical Sciences, King’s College London, Guy’s Hospital, London, UKDepartment of Informatics, Faculty of Natural, Mathematical & Engineering Sciences, King’s College London, Bush House, London, UKBarts Cancer Institute, Queen Mary University of London, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKSt. John’s Institute of Dermatology, School of Basic & Medical Biosciences, King’s College London, Guy’s Hospital, London, UKThe application of monoclonal antibodies (mAbs) for the treatment of melanoma has significantly improved the clinical management of this malignancy over the last decade. Currently approved mAbs for melanoma enhance T cell effector immune responses by blocking immune checkpoint molecules PD-L1/PD-1 and CTLA-4. However, more than half of patients do not benefit from treatment. Targeting the prominent myeloid compartment within the tumor microenvironment, and in particular the ever-abundant tumor-associated macrophages (TAMs), may be a promising strategy to complement existing therapies and enhance treatment success. TAMs are a highly diverse and plastic subset of cells whose pro-tumor properties can support melanoma growth, angiogenesis and invasion. Understanding of their diversity, plasticity and multifaceted roles in cancer forms the basis for new promising TAM-centered treatment strategies. There are multiple mechanisms by which macrophages can be targeted with antibodies in a therapeutic setting, including by depletion, inhibition of specific pro-tumor properties, differential polarization to pro-inflammatory states and enhancement of antitumor immune functions. Here, we discuss TAMs in melanoma, their interactions with checkpoint inhibitor antibodies and emerging mAbs targeting different aspects of TAM biology and their potential to be translated to the clinic.https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127284melanomamacrophagesmonoclonal antibodiesimmunotherapycheckpoint inhibitorspolarization |
| spellingShingle | Rebecca Adams Gabriel Osborn Bipashna Mukhia Roman Laddach Zena Willsmore Alicia Chenoweth Jenny L C Geh Alastair D MacKenzie Ross Ciaran Healy Linda Barber Sophia Tsoka Victoria Sanz-Moreno Katie E Lacy Sophia N Karagiannis Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies OncoImmunology melanoma macrophages monoclonal antibodies immunotherapy checkpoint inhibitors polarization |
| title | Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies |
| title_full | Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies |
| title_fullStr | Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies |
| title_full_unstemmed | Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies |
| title_short | Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies |
| title_sort | influencing tumor associated macrophages in malignant melanoma with monoclonal antibodies |
| topic | melanoma macrophages monoclonal antibodies immunotherapy checkpoint inhibitors polarization |
| url | https://www.tandfonline.com/doi/10.1080/2162402X.2022.2127284 |
| work_keys_str_mv | AT rebeccaadams influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT gabrielosborn influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT bipashnamukhia influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT romanladdach influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT zenawillsmore influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT aliciachenoweth influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT jennylcgeh influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT alastairdmackenzieross influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT ciaranhealy influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT lindabarber influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT sophiatsoka influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT victoriasanzmoreno influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT katieelacy influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies AT sophiankaragiannis influencingtumorassociatedmacrophagesinmalignantmelanomawithmonoclonalantibodies |